3-Year EPCORE NHL-1 Data Published Showing 53% Have Deep, Durable Remission
AJMC,
In a trial that started with patients heavily pretreated for large B-cell lymphoma (LBCL), more than half who achieved a…
Epcoritamab Elicited Sustained PFS and OS at 3 Years in R/R LBCL
Cancer Network,
Epcoritamab monotherapy led to long-term disease-free remissions in patients with relapsed/refractory large B-cell lymphoma who…
Epcoritamab Maintains Responses at 3 Years in Relapsed/Refractory LBCL
OncLive,
Epcoritamab in Relapsed/Refractory LBCL | Image credit: © Bipul Kumar - stock.adobe.com Epcoritamab-bysp (Epkinly) led to…
Epcoritamab Elicits Durable CR Rates, Increases MRD Negativity in Relapsed/Refractory DLBCL
OncLive,
Julie M. Vose, MD, MBA Of the FDA-approved bispecific antibodies for patients with relapsed/refractory large B-cell lymphoma (LBC…